Back to Search
ReviewUnknown

Looking beyond COVID-19 vaccine phase 3 trials

Author Affiliations
International Vaccine Institute, University of Antananarivo, University of Cambridge, International Centre for Diarrhoeal Disease Research, ...
Published InNature Medicine
Year2021
Citations632

Abstract

After the recent announcement of COVID-19 vaccine efficacy in clinical trials by several manufacturers for protection against severe disease, a comprehensive post-efficacy strategy for the next steps to ensure vaccination of the global population is now required. These considerations should include how to manufacture billions of doses of high-quality vaccines, support for vaccine purchase, coordination of supply, the equitable distribution of vaccines and the logistics of global vaccine delivery, all of which are a prelude to a massive vaccination campaign targeting people of all ages. Furthermore, additional scientific questions about the vaccines remain that should be answered to improve vaccine efficacy, including questions regarding the optimization of vaccination regimens, booster doses, the correlates of protection, vaccine effectiveness, safety and enhanced…
View at Publisher

BORR does not host full-text PDFs. The button above takes you to the original publisher.